Used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). It functions as a selective inhibitor of Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway. By blocking BTK, it disrupts signals that promote malignant B-cell proliferation and survival, leading to reduced tumor growth. Currently investigated in clinical trials either as monotherapy or in combination with other agents like rituximab or chemotherapy regimens. Shows potential for patients who are refractory to other treatments due to its targeted mechanism and favorable pharmacokinetic profile.